Search results
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 3 days agoA Phase 3 study is already underway with the initial results expected later this decade. But at...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks· 2 days agoFree Report) reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks Consensus Estimate of $1.94. Earnings rose 48% year over year on a reported basis and 54% ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoInnovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting PR Newswire SAN FRANCISCO and SUZHOU, China, April 24, 2024 SAN FRANCISCO and SUZHOU, China, April 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("
Mirae Asset Global Investments Co. Ltd. Trims Stock Position in Iovance Biotherapeutics, Inc....
ETF DAILY NEWS· 4 days agoMirae Asset Global Investments Co. Ltd. trimmed its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 3.4% during the fourth quarter, according to its ...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 days agoTurning...grew 24% to $6.9 billion driven by increased uptake from earlier-stage cancers and continued strong demand from metastatic indications....
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 5 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoNew York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 5 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 2 days agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 3 days agoThe NDA is supported by results from JUPITER-02, a randomized, double...
